---
schema_version: "secwatch.filing_event.v1"
accession: "0001818331-22-000068"
form_type: "8-K"
ticker: "WGS"
cik: "0001818331"
company_name: "GeneDx Holdings Corp."
filed_at: "2022-08-15T23:59:59+00:00"
generated_at: "2026-06-24T00:01:30.174347+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Sema4 Q2 revenue $36.2M, net loss $85.7M; exits somatic testing, cuts 13% workforce; founder Schadt resigns

## Summary
- Q2 total revenue $36.2M (or $66.3M excluding $30.1M prior-period adjustments); net loss $85.7M; adjusted net loss $72.9M.
- Exiting somatic tumor testing (<1% revenue, ~$35M annual expense); eliminating ~250 positions (~13% workforce), cumulative 30% role reduction.
- Founder Eric Schadt resigns as President, Chief R&D Officer, and board member; Matthew Davis (ex-Invitae) named Chief Technology & Product Officer.
- FY2022 revenue guidance $245-255M; adj. gross margin 4-9% (incl. $24M prior-period adjustment); expects >$165M cash by year-end.

## SEC filing metadata
- accession: 0001818331-22-000068
- form_type: 8-K
- ticker: WGS
- cik: 0001818331
- company_name: GeneDx Holdings Corp.
- filed_at: 2022-08-15T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818331/000181833122000068/0001818331-22-000068-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818331/000181833122000068/smfr-20220815.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001818331-22-000068
- JSON: https://secwatch.observer/filing/0001818331-22-000068.json
- Plain text: https://secwatch.observer/filing/0001818331-22-000068.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.